Fast Biopharma, a UK company based in Oxford and Alderley Park, seeks to address the failure of checkpoint inhibitor therapy in the majority of cancer patients by targeting T-cell death. Fas ligand is expressed on multiple cell types within the microenvironment of certain solid tumours and is thought to be a major limiter of activated T-cell trafficking and persistence. Our first-in-class anti-fasL antibody, FBP002, is an ideal humanised antibody to progress this concept into the clinic.